Key result
In a canine model of reperfused STEMI, candesartan administered at reperfusion attenuated age-dependent early increases in markers of damage and adverse structural and matrix remodeling.
Why the study?
Does candesartan administered at the time of reperfusion attenuate age-related increases in reperfusion injury and left ventricular remodeling in a canine model of reperfused STEMI?
Population
Dogs in 3 age groups with reperfused ST-segment-elevation myocardial infarction
Comparison
Candesartan administered over 30 minutes from… vs Placebo
Design
Preclinical, Randomized
Follow-up
2 hours of reperfusion
Authors
Loading...
Does not support clinical adoption; hypothesis-generating for age-specific ARB effects in reperfused STEMI models.
RCT
Does candesartan administered at the time of reperfusion attenuate age-related increases in reperfusion injury and left ventricular remodeling in a canine model of reperfused STEMI?
In a canine model of reperfused STEMI, early administration of candesartan at the time of reperfusion attenuated age-related increases in reperfusion injury and adverse ventricular remodeling.
Jugdutt et al. (2010) conducted an RCT in Reperfused ST-segment-elevation myocardial infarction. Candesartan vs. Placebo was evaluated on Markers of damage, structural remodeling, extracellular matrix remodeling, and inflammation. In a canine model of reperfused STEMI, candesartan administered at reperfusion attenuated age-dependent early increases in markers of damage and adverse structural and matrix remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: